Savara Inc Increase (Decrease) in Accrued Liabilities
Savara Inc (SVRA) reported Increase (Decrease) in Accrued Liabilities of $1.73 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2017-05-09
- Savara Inc increase (decrease) in accrued liabilities for the quarter ending 2017-03-31 was $1.73M.
- Savara Inc increase (decrease) in accrued liabilities for the quarter ending 2016-03-31 was -$358.00K.
- Savara Inc increase (decrease) in accrued liabilities for fiscal 2016 was -$6.98M, a 364.71% decline from fiscal 2015.
- Savara Inc increase (decrease) in accrued liabilities for fiscal 2015 was $2.64M, a 26.95% increase from fiscal 2014.
- Savara Inc increase (decrease) in accrued liabilities for fiscal 2014 was $2.08M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|
| 2017-03-31 | $1.73M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$6.98M 10-K · filed 2017-03-06 | |
| 2016-03-31 | -$358.00K 10-Q · filed 2017-05-09 | |
| 2015-12-31 | $2.64M 10-K · filed 2017-03-06 | |
| 2014-12-31 | $2.08M 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |